skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Maraviroc in the treatment of HIV infection

Review

(3177) Views  (1046) Full article downloads

Authors: Neelanjana Ray

Published Date August 2008 Volume 2008:2 Pages 151 - 161
DOI: http://dx.doi.org/10.2147/DDDT.S3474

Neelanjana Ray

Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA

Abstract: While a successful HIV vaccine will likely take several more years to become a reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their efficacious use has improved the quality of life and life expectancy of millions of HIV-infected individuals. A recent addition to these ARVs is a new class of drug that targets the HIV entry process by interfering with the action of the CCR5 coreceptor. The first licensed member of this class is a drug called maraviroc, which is also the first ARV that targets a cellular rather than a viral protein. Several other CCR5 antagonists with varied mechanisms of action are being developed. Key issues with the use of these drugs include determining their potential for use in treatment-naïve versus treatment-experienced patients, the development of sensitive coreceptor phenotyping assays to determine patient eligibility, and finally monitoring the emergence of resistant viruses and their mechanisms of resistance. This review summarizes the preclinical and clinical development of maraviroc as well as studies of HIV resistance to this drug both in vitro and in patients. In addition, a range of diverse CCR5 antagonists currently under development, are also discussed.

Keywords: HIV, coreceptor usage, CCR5 inhibitor, maraviroc, drug resistance








Readers of this article also read:

Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent
Structure-based design of anticancer prodrug PABA/NO
Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
Raltegravir in the management of HIV-infected patients
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Erratum
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University